Identification of good and poor prognosis HPV associated oropharyngeal cancer based on CD103 immune cell expression in patients treated with cetuximab and radiotherapy on TROG 12.01 and De-ESCALaTE randomized trials.

Danny Rischin; Hisham Mohamed Mehanna; Richard J Young; Mathias Bressel; Janet Dunn; June Corry; Tessa Fulton-Lieuw; Gulnaz Iqbal; Lizbeth M Kenny; Sandro Porceddu; Christopher Wratten; Max Robinson; Benjamin J Solomon

Conference Proceedings

Identification of good and poor prognosis HPV associated oropharyngeal cancer based on CD103 immune cell expression in patients treated with cetuximab and radiotherapy on TROG 12.01 and De-ESCALaTE randomized trials.

Danny Rischin, Hisham Mohamed Mehanna, Richard J Young, Mathias Bressel, Janet Dunn, June Corry, Tessa Fulton-Lieuw, Gulnaz Iqbal, Lizbeth M Kenny, Sandro Porceddu, Christopher Wratten, Max Robinson, Benjamin J Solomon

JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021

DOI: 10.1200/jco.2021.39.15_suppl.109

Abstract

109 Background: Trials in human papilloma virus associated oropharyngeal squamous cell carcinoma (HPVOPSCC), substituting cetuximab (CETUX) for cisplatin (CIS) with radiotherapy (RT), resulted in decreased efficacy without improved toxicity or symptom burden. We reported that high intratumoral immune cell (ITIC) CD103 expression (> 30%), a marker of tissue-resident memory T cells, is associated with better prognosis in unselected patients with HPVOPSCC treated with CIS/RT. In this study our aim was to determine whether low risk HPVOPSCC patients treated with CETUX/RT with high CD103 have a superior prognosis. Methods: TROG 12.01 and De-ESCALaTE are randomised multicentre trials that compare..

View full abstract